What is Merck KGaA's P/E and P/B ratio?

Merck KGaA has a P/E ratio of 26.9 and a P/B ratio of 2.14.

What is Merck KGaA's debt-to-equity ratio?

Merck KGaA has a debt-to-equity ratio of 0.41.

How much does Merck KGaA owe compared with what it owns?

Merck KGaA owes €0.44 for every €1 it owns (balance sheet Mar 2026), which is low.

Does Merck KGaA have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Merck KGaA.

Where can I read the latest news about Merck KGaA?

Recent headlines about Merck KGaA from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Merck KGaA have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Merck KGaA's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Merck KGaA (MRK) Stock Price Analysis

Q: What is Merck KGaA's Positivity rank?

Merck KGaA is ranked #4,332 of 6,767 companies globally and #23 of 38 in Germany on PositoAI, with a Positivity Score of 19,580.

Merck KGaA — Overview & Financial Snapshot

Merck KGaA (XETRA: MRK) is a Healthcare company, ranked #4,332 of 6,767 companies globally and #23 of 38 in Germany on PositoAI, with a Positivity Score of 19,580. Its market capitalisation is ₹6.75 lakh Cr (€63.63B), P/E ratio is 26.9 and P/B ratio is 2.14. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Powered by OpenAI

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Merck KGaA